What is the optimal treatment for a multidrug-resistant Pseudomonas urinary tract infection in a patient with bilateral double‑J ureteral stents?

Treatment of MDR Pseudomonas Urinary Infection in Bilateral DJ Stent Patient

For a patient with bilateral double-J stents and multidrug-resistant Pseudomonas urinary tract infection, initiate intravenous ceftolozane-tazobactam 1.5 g three times daily or ceftazidime-avibactam 2.5 g three times daily based on susceptibility testing, combined with urgent stent removal or exchange to eliminate the biofilm source. 1, 2

Critical First Steps

This is a complicated UTI (cUTI) by definition due to the presence of bilateral ureteral stents, which create anatomic abnormalities and serve as biofilm reservoirs that make infection eradication extremely challenging 1. The presence of MDR Pseudomonas elevates this to a high-risk scenario requiring aggressive management.

Immediate Management Algorithm:

1. Obtain urine culture with susceptibility testing - This is non-negotiable before finalizing therapy
2. Assess for sepsis/septic shock - Check vital signs, lactate, and end-organ function
3. Imaging evaluation - Ultrasound or CT to rule out obstruction, abscess, or pyelonephritis
4. Source control planning - Coordinate urgent stent removal/exchange with urology

Antibiotic Selection for MDR Pseudomonas

First-Line Parenteral Options (Based on Susceptibility):

The 2024 EAU guidelines specifically recommend for MDR organisms 1:

• Ceftolozane-tazobactam 1.5 g IV three times daily - Preferred for difficult-to-treat Pseudomonas 2
• Ceftazidime-avibactam 2.5 g IV three times daily - Alternative first-line option
• Cefiderocol 2 g IV three times daily - Reserved for extensively resistant strains or metallo-β-lactamase producers 1

Alternative Options if Above Unavailable:

• Meropenem 1 g IV three times daily - Only if MIC ≤8 mg/L and used with extended infusion 2
• Cefepime 2 g IV twice daily - If susceptible
• Piperacillin-tazobactam 4.5 g IV three times daily - If susceptible
• Aminoglycosides (amikacin 15 mg/kg daily or plazomicin 15 mg/kg daily) - Can be used for short duration in combination or as monotherapy for non-severe cUTI if active in vitro 1, 2

Critical Caveat on Combination Therapy:

Do NOT use combination therapy if treating with ceftolozane-tazobactam, ceftazidime-avibactam, or cefiderocol - monotherapy is recommended for these agents 2. Combination therapy is only suggested for extremely resistant strains susceptible only to older agents (polymyxins, aminoglycosides, tigecycline, fosfomycin) 2.

Source Control: The Non-Negotiable Component

Stent removal or exchange is essential for cure - antibiotics alone will NOT eradicate biofilm-associated infections 3, 4. The bilateral stents harbor biofilm-forming Pseudomonas that are protected from antibiotic penetration.

Timing of Stent Management:

• Immediate removal/exchange if patient is septic or clinically unstable
• Within 24-48 hours if stable but infected
• Consider percutaneous nephrostomy if stents cannot be safely removed immediately 5

The biofilm on stents creates a persistent reservoir where bacteria are 100-1000 times more resistant to antibiotics than planktonic forms 3, 4. Studies show that 24% of diabetic patients with DJ stents develop biofilm colonization, with even higher rates in those with prolonged stent duration 6.

Treatment Duration

• 7-14 days of IV antibiotics for cUTI without upper tract involvement
• 14-21 days if pyelonephritis or systemic involvement present
• Duration should be calculated from the time of source control (stent removal), not from antibiotic initiation

Monitoring and De-escalation

What to Monitor:

• Clinical response within 48-72 hours (defervescence, symptom improvement)
• Repeat urine culture 48-72 hours after starting appropriate therapy
• Imaging if no clinical improvement by 72 hours 1

De-escalation Strategy:

Once patient is clinically stable and susceptibilities are known, consider step-down to targeted oral therapy if available 2:

• Ciprofloxacin 500-750 mg twice daily (only if susceptible and fluoroquinolone resistance <10%)
• Levofloxacin 750 mg daily (same caveat)

However, for MDR Pseudomonas, oral options are often limited or non-existent, necessitating completion of IV therapy.

Common Pitfalls to Avoid

1. Using fluoroquinolones empirically - Resistance rates are extremely high (87.5-93.7% in recent studies) 6, 7
2. Delaying stent removal - Antibiotics alone have minimal efficacy against biofilm infections
3. Using tigecycline - Strongly NOT recommended for UTIs, especially bloodstream infections 2
4. Underdosing or using standard infusions - Extended infusions of β-lactams improve outcomes
5. Using nitrofurantoin or fosfomycin - Insufficient data for complicated UTIs and specifically avoided in guidelines 1

Special Considerations for This Patient

Risk Factors to Address:

• Bilateral stents increase infection risk exponentially
• Assess for diabetes, renal impairment, immunosuppression - these worsen outcomes 6
• Duration of stent placement - stents >30 days have significantly higher infection rates 6
• Hydration status - inadequate fluid intake (<2000 mL/day) increases risk 6

If Extremely Resistant (Carbapenem-Resistant):

For carbapenem-resistant Pseudomonas aeruginosa (CRPA), the hierarchy is 2, 8, 5:

1. Ceftolozane-tazobactam (if susceptible)
2. Ceftazidime-avibactam (if susceptible)
3. Cefiderocol (for metallo-β-lactamase producers or pan-resistant strains)
4. Cefepime-zidebactam (investigational but showing promise) 5
5. Combination therapy with aztreonam + ceftazidime-avibactam for metallo-β-lactamase producers 2

Novel Consideration:

One case report describes successful use of bacteriophage therapy for refractory Pseudomonas UTI in a patient with bilateral stents after antibiotic failure 9. While not standard practice, this may be considered in consultation with infectious disease specialists for truly untreatable cases.

Antibiotic Stewardship Note

The new β-lactam/β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam, cefiderocol) should be reserved for confirmed MDR organisms to preserve their efficacy 2. However, in this clinical scenario with confirmed MDR Pseudomonas and bilateral stents, their use is entirely appropriate and guideline-concordant.